Cost-effectiveness analysis of the 20-valent pneumococcal conjugate vaccine for the pediatric population in South Korea
Vaccine,
Год журнала:
2024,
Номер
42(22), С. 126000 - 126000
Опубликована: Июнь 5, 2024
To
evaluate
the
cost-effectiveness
of
20-valent
pneumococcal
conjugate
vaccine
(PCV20)
compared
to
13-valent
(PCV13)
for
pediatric
population
in
Korea,
where
four-dose
coverage
rate
is
over
97%.
Язык: Английский
Global Assessment of Health Utilities Associated with Pneumococcal Disease in Children—Targeted Literature Reviews
PharmacoEconomics,
Год журнала:
2025,
Номер
unknown
Опубликована: Май 23, 2025
Язык: Английский
Cost-effectiveness analysis of 20-valent pneumococcal conjugate vaccine (PCV20) to prevent pneumococcal disease in the Greek pediatric population
C. Tzanetakos,
Ioanna Kokkinaki,
Myrto Barmpouni
и другие.
Expert Review of Vaccines,
Год журнала:
2025,
Номер
unknown
Опубликована: Июнь 3, 2025
The
aim
of
the
present
study
was
to
evaluate
cost-effectiveness
20-valent
pneumococcal
conjugate
vaccine
(PCV20)
compared
13-valent
(PCV13)
and
15-valent
(PCV15)
for
prevention
disease
in
pediatric
population
Greece.
A
published
decision-analytic
Markov
model
adapted
from
payer
perspective,
compare
PCV20
(under
a
3
+
1
dosing
schedule
per
EMA
approval)
with
PCV13
PCV15
(both
under
2
schedule)
over
10-year
time
horizon.
Inputs
epidemiology,
serotype
coverage,
effectiveness,
utilities,
direct
medical
costs
(€2024)
were
sourced
literature
official
data.
Model
outcomes
included
number
invasive
(IPD),
noninvasive
hospitalized
pneumonia,
non-hospitalized
pneumonia
otitis
media
(OM)
cases,
attributable
deaths,
costs,
quality-adjusted
life-years
(QALYs)
each
vaccination
strategy
incremental
ratios
comparison.
Scenario
analyses
assessed
recent
national
recommendations.
analysis
indicated
that,
prevents
an
additional
1,953
1,514
cases
IPD
54,956
42,069
343,353
271,864
OM
1,377
987
deaths
respectively,
resulting
gain
23,065
(vs
PCV13)
17,118
PCV15)
QALYs
respectively.
lower
PCV15,
translated
reduction
total
care
cost
€249
M
vs
€192
modeled
showed
that
remained
dominant
schedule.
Vaccination
PCV20,
whether
or
schedule,
estimated
be
Greek
infants,
as
expansion
coverage
morbidity
costs.
Язык: Английский
Cost-Effectiveness Analysis of Pneumococcal Vaccine in the Pediatric Population: A Systematic Review
Опубликована: Авг. 12, 2024
Pneumococcal
disease,
caused
by
Streptococcus
pneumoniae
is
the
leading
cause
of
high
mortality
in
children
worldwide.
The
tremendous
direct
cost
hospital
admissions
and
significant
indirect
costs
from
productivity
loss
contributed
considerably
to
economic
burden,
with
vaccination
being
only
efficient
way
against
illness.
Our
study
aims
summarize
cost-effectiveness
pneumococcal
conjugate
vaccine
(PCV)
implemented
pediatric
population.
Employing
online
databases
Pubmed,
Embase,
Medline,
we
looked
for
evaluation
2018
until
March
2024.
Incremental
Cost-Effectiveness
Ratios
(ICER)
Quality-Adjusted-Life-Years
(QALY)
were
primary
outcomes
measuring
PCV's
cost-effectiveness.
A
28-item
CHEERS
2022
checklist
was
applied
assess
quality
collected
studies.
Of
16
papers
found,
9/16
discussed
lower-valent
(PCV13,
PCV10)
7/16
examined
higher-valent
vaccine.
(PCV20,
PCV15).
PCV13
PCV10
required
more
generated
QALY
compared
no
vaccination.
Both
PCV15
PCV20
averted
substantial
healthcare
yielded
greater
life
than
PCV13.
Additionally,
a
dominant
strategy
PCV15.
Utilizing
very
cost-effective
option
not
getting
vaccinated.
Transitioning
would
result
higher
gain
cost-saving
switching
Язык: Английский
Cost-Effectiveness Analysis of Pneumococcal Vaccines in the Pediatric Population: A Systematic Review
Healthcare,
Год журнала:
2024,
Номер
12(19), С. 1950 - 1950
Опубликована: Сен. 29, 2024
Objectives:
Pneumococcal
disease,
caused
by
Streptococcus
pneumoniae,
is
the
leading
cause
of
mortality
in
children
worldwide.
The
tremendous
direct
cost
hospital
admissions
and
significant
indirect
costs
from
productivity
loss
contribute
considerably
to
its
economic
burden,
with
vaccination
being
only
efficient
protection
against
illness.
Our
study
aims
summarize
cost-effectiveness
pneumococcal
conjugate
vaccine
(PCV)
implemented
pediatric
population.
Methods:
Employing
online
databases
PubMed,
Embase,
Medline,
we
looked
for
evaluations
2018
until
March
2024.
Incremental
Cost-Effectiveness
Ratios
(ICER)
Quality-Adjusted
Life
Years
(QALY)
were
primary
outcomes
measuring
PCVs.
A
28-item
CHEERS
2022
checklist
was
applied
assess
quality
collected
studies.
Results:
Of
16
papers
found,
9/16
discussed
lower-valent
vaccines
(PCV13,
PCV10)
7/16
examined
higher-valent
(PCV20,
PCV15).
PCV13
PCV10
involved
greater
generated
more
QALY
compared
no
vaccination.
Both
PCV15
PCV20
averted
substantial
healthcare
yielded
life
than
PCV13.
Additionally,
a
dominant
strategy
PCV15.
Conclusions:
Utilizing
very
cost-effective
option
not
getting
vaccinated.
Transitioning
would
result
higher
gain
cost-saving
switching
Язык: Английский
Pediatric Otitis Media in the New Pneumococcal Conjugate Vaccines Era: What’s Next?
The Pediatric Infectious Disease Journal,
Год журнала:
2024,
Номер
43(6), С. 604 - 605
Опубликована: Март 19, 2024
*From
the
Department
of
Otolaryngology-Head
and
Neck
Surgery,
Samson
Assuta
Ashdod
University
Hospital,
Ashdod,
Israel
†Faculty
Health
Sciences,
Ben-Gurion
Negev,
Be'er-Sheva,
Israel.
Accepted
for
publication
February
28,
2024
The
authors
have
no
funding
or
conflicts
interest
to
disclose.
Address
correspondence:
Tal
Marom,
M.D.,
Hospital
Faculty
7,
Harefu'ah
street,
7747629,
E-mail:
[email
protected],
protected].
Язык: Английский
Cost-Effectiveness Analysis of Routine Childhood Immunization with 20-Valent versus 15-Valent Pneumococcal Conjugate Vaccines in Germany
Vaccines,
Год журнала:
2024,
Номер
12(9), С. 1045 - 1045
Опубликована: Сен. 12, 2024
This
study
aimed
to
evaluate
the
cost-effectiveness
of
routine
childhood
immunization
with
20-valent
pneumococcal
conjugate
vaccine
(PCV20)
in
a
four-dose
regimen
(3
+
1
schedule)
versus
15-valent
PCV
(PCV15/V114)
three-dose
(2
1)
Germany.
The
utilized
decision-analytic
Markov
model
estimate
lifetime
costs
and
effectiveness
outcomes
for
single
birth
cohort
tracked
incidence
acute
infections
long-term
meningitis
sequelae
both
vaccination
strategies.
data
were
derived
from
published
clinical
trials
observational
studies
PCV7
PCV13.
Indirect
effects,
such
as
herd
protection
serotype
replacement,
included
model.
adopted
societal
perspective,
including
direct
medical,
non-medical,
indirect
costs.
Scenario
sensitivity
analyses
performed.
In
base
case,
PCV20
prevented
more
disease
cases
deaths,
an
expected
gain
96
quality-adjusted
life
years
(QALYs)
compared
V114.
However,
was
associated
total
incremental
cost
EUR
48,358,424,
resulting
ratio
(ICER)
503,620/QALY.
Most
scenario
estimated
that
ICER
exceeded
150,000/QALY.
Routine
instead
V114
may
not
be
economically
efficient
use
healthcare
resources
Язык: Английский
The Health and Economic Effects of PCV15 and PCV20 During the First Year of Life in the US
Vaccines,
Год журнала:
2024,
Номер
12(11), С. 1279 - 1279
Опубликована: Ноя. 14, 2024
(1)
Background/Objectives:
Two
pneumococcal
conjugate
vaccines,
15-(PCV15)
and
20-(PCV20)
valent
formulations,
are
routinely
recommended
for
US
children
in
a
3+1
schedule.
The
first
three
doses
administered
during
the
year
of
life
at
2,
4,
6
months,
while
booster
dose
is
given
12
to
15
months.
This
study
evaluated
health
economic
effects
PCV20
infant
series
within
compared
PCV15.
(2)
Methods:
Using
decision-analytic
model,
we
calculated
introducing
PCV15
or
five
subsequent
birth
cohorts.
Epidemiological
data
were
drawn
from
peer-reviewed
studies
estimates
vaccine
effectiveness
extrapolated
established
PCV13
PCV7
efficacy
studies.
Direct
medical
costs
related
disease
treatment
extracted
literature
inflated
2024
dollars.
(3)
Results:
Over
course
years,
implementation
vaccination
newborns
United
States,
PCV15,
projected
prevent
an
additional
220
cases
invasive
disease,
6542
community-acquired
pneumonia,
112,095
otitis
media
across
strategy
could
66
deaths
linked
these
illnesses
confer
extra
gains,
amounting
5058
years
5037
quality-adjusted
years.
These
prevented
estimated
save
approximately
USD
147
million
over
5
(4)
Conclusions:
demonstrated
that
vaccinating
with
months
would
yield
substantially
greater
return
due
serotypes
covered
by
PCV20.
Язык: Английский
Prevalence of nasopharyngeal Streptococcus Pneumoniae carriage in infants: A systematic review and meta-analysis of cohort studies and randomized controlled trials
PLoS ONE,
Год журнала:
2024,
Номер
19(12), С. e0315461 - e0315461
Опубликована: Дек. 18, 2024
This
study
aims
to
examine
the
prevalence
of
nasopharyngeal
Streptococcus
pneumoniae
carriage
(NSPC)
in
infants
during
their
first
two
years
life
and
compare
rates
among
different
vaccine
groups
country
income-levels.
will
be
achieved
through
a
systematic
review
published
literature,
specifically
focusing
on
data
from
cohort
studies
randomized
controlled
trials.
A
comprehensive
search
was
conducted
four
electronic
databases:
PubMed,
Web
Science,
ScienceDirect,
Scopus,
using
predefined
strategy.
Forty-nine
articles
met
inclusion
criteria
for
this
review.
According
results
obtained
random
effects
model,
pooled
mean
NSPC
1.68%
at
birth
(95%
CI
[0.50;
5.47]),
24.38%
1
4
months
[19.06;
30.62]),
48.38%
6
[41.68;
55.13]),
59.14%
7
9
[50.88;
66.91]),
48.41%
10
12
[41.54;
55.35]),
42.00%
13
18
[37.01;
47.16]),
48.34%
19
24
[38.50;
58.31]).
The
highest
were
observed
children
aged
across
all
groups.
Low-income
countries
consistently
demonstrated
age
categories
studied.
meta-analysis
provide
robust
evidence
high
groups,
with
persistent
regional
disparities,
especially
low-income
countries.
highlights
need
continuous
monitoring
trends,
particularly
emergence
non-vaccine
serotypes.
Policymakers
healthcare
providers
should
leverage
these
findings
enhance
vaccination
strategies,
aiming
minimize
overall
burden
pneumococcal
diseases
infants.
Язык: Английский